Zevra Therapeutics (Zevra Therapeutics) EBIT : $-44.55 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Zevra Therapeutics EBIT?

Zevra Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-14.40 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-44.55 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Zevra Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 was -67.77%. Zevra Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -4,018.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Zevra Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -26.97%.

Zevra Therapeutics EBIT Historical Data

The historical data trend for Zevra Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zevra Therapeutics EBIT Chart

Zevra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-18.03

-5.70

-8.15

-26.47

-44.55

Zevra Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT	Get a 7-Day Free Trial															6.64	-11.69	-4.96	-13.50	-14.40

Competitive Comparison of Zevra Therapeutics's EBIT

For the Biotechnology subindustry, Zevra Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zevra Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's EV-to-EBIT falls into.

Zevra Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-44.55 Mil.

Zevra Therapeutics (NAS:ZVRA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Zevra Therapeutics's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-58.684 * ( 1 - 0% )	/	( (42.476	+	130.706)	/ 2 )
=	-58.684	/	86.591
=	-67.77 %

where

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	138.982	-	13.08	-	( 83.426	-	max(0, 21.714	-	137.013	+	83.426	))
=	42.476

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	172.327	-	28.403	-	( 67.737	-	max(0, 73.72	-	86.938	+	67.737	))
=	130.706

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Zevra Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-57.588	/	( ( (1.34 + max(-9.693, 0))	+	(1.526 + max(-17.534, 0)) )	/	2 )
=	-57.588	/	( ( 1.34	+	1.526 )	/	2 )
=	-57.588	/	1.433
=	-4,018.70 %

where Working Capital is:

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(9.927	+	0	+	1.661)	-	(13.08	+	0	+	8.201)
=	-9.693

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(16.119	+	0	+	1.824)	-	(28.403	+	0	+	7.074)
=	-17.534

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Zevra Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	-44.548	/	165.192
	=	-26.97 %

Zevra Therapeutics EBIT Related Terms

Thank you for viewing the detailed overview of Zevra Therapeutics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Zevra Therapeutics (Zevra Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zevra Therapeutics Inc (NAS:ZVRA) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

1GDA:Germany

Address

1180 Celebration Boulevard, Suite 103, Celebration, FL, USA, 34747

Website

https://www.zevra.com

Zevra Therapeutics Inc is a rare disease company melding science, data and patient needs to create transformational therapies for diseases with limited or no treatment options. The firm's data-driven clinical, regulatory, and commercialization strategies overcome complex drug development challenges to bring much-needed therapies to patients. Its product candidate comprises Arimoclomol, orally delivered investigational product candidate for the treatment of Niemann-Pick type C (NPC). KP1077 is Zevra's lead clinical candidate being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy.

Executives

Neil F. Mcfarlane	director, officer: President and CEO	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
R. Laduane Clifton	officer: VP Fin & Corp Controller	C/O KEMPHARM, INC., 1170 CELEBRATION BLVD., #103, CELEBRATION FL 34747
Thomas Anderson	director	215 FIRST STREET, CAMBRIDGE MA 02142
Joshua Schafer	officer: CCO & EVP, Bus. Development	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
John B Bode	director	C/O TRIBUNE PUBLISHING COMPANY, 202 W. FIRST STREET, LOS ANGELES CA 90012
Watton Corey Michael	director	22045 KAREN STREET, ELKHORN NE 68022
Douglas W Calder	director	324 S. HYDE PARK AVENUE, SUITE 350, TAMPA FL 33606
Wendy L Dixon	director
Tamara A Seymour	director	C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Timothy J. Sangiovanni	officer: VP, Corporate Controller	C/O KEMPHARM, INC., 2500 CROSSPARK RD, STE E-126, CORALVILLE IA 52241
Matthew R Plooster	director	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
David S Tierney	director	C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Richard W Pascoe	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Christopher Posner	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Travis C Mickle	director, 10 percent owner, officer: President & CEO	2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241